Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD)



Status:Completed
Conditions:Alzheimer Disease
Therapuetic Areas:Neurology
Healthy:No
Age Range:55 - Any
Updated:4/13/2015
Start Date:May 2010
End Date:July 2015
Contact:Angela R Van Sciver, BA
Email:avansciver@kumc.edu
Phone:913-945-5029

Use our guide to learn which trials are right for you!

Alzheimer's Disease Exercise Prevention Trial

The current project is a natural extension of a programmatic line of investigation into the
relationship between exercise, brain aging, and AD that Dr. Burns has developed over the
last four years. The current study will provide data to estimate expected effect sizes for
power analyses and sample size calculations. It will also provide an opportunity to
optimally design a larger trial that can be extended to multiple sites to more definitively
examine the role of exercise as a therapy in AD. The current project's aims are an
important and necessary developmental step given the lack of fitness data in AD and the
limited knowledge of the mechanisms that may form the basis of an association between
aerobic fitness and AD.


Inclusion Criteria:

- Informed consent provided by the participant or the participant's legally acceptable
representative

- Age 55 years or older

- Diagnosis of Probable AD according to the National Institute of Neurological and
Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders
Association (NINCDS-ADRDA)

- Clinical Dementia Rating (CDR) of 0.5 (very mild) or 1 (mild dementia)

- Mini-Mental Status Exam Score of 16 to 30, inclusive.

- Rosen Modified Hachinski score of 4 or less

- Community dwelling with a caregiver able and willing to accompany the participant on
all visits, if necessary. The caregiver must visit with the subject more than five
times a week for the duration of the study.

- Underactive or sedentary as determined by a Telephone Assessment of Physical
Activity.

- Adequate visual and auditory abilities to perform all aspects of the cognitive and
functional assessments

- Stable doses of medications for at least 30 days prior to screening. Cholinesterase
inhibitors and memantine are allowed provided the participant is on stable doses
without clinically significant side effects for 60 days. Additionally, the
participant and caregiver will agree, barring unforeseen circumstances, to continue
the same regimen for the trial duration.

- Likely to participate in all scheduled evaluations and complete the 26 week program.

Exclusion Criteria:

- CDR 0.5 uncertain dementia (i.e., not meeting NINCDS-ADRDA criteria).

- Significant neurological disease, other than AD, that may affect cognition

- MRI or CT scan indicative of significant abnormalities that may explain cognitive
decline (e.g., multiple lacunar infarcts or a single prior infarct > 1 cm3,
micro-hemorrhages or evidence of a prior hemorrhage > 1 cm3, evidence of cerebral
contusion, encephalomalacia, aneurysm, vascular malformation, or space-occupying
lesion such as an arachnoid cyst or brain tumor)

- Current clinically significant major psychiatric disorder (e.g., Major Depressive
Disorder) according to DSM-IV criteria or significant psychiatric symptoms (e.g.,
hallucinations) that could impair the completion of the study. Individuals with
depressive symptoms (Geriatric Depression Scale < 6) and who do not meet criteria for
major depression will be eligible.

- Current clinically-significant systemic illness that is likely to result in
deterioration of the patient's condition or affect the patient's safety during the
study

- History of clinically-evident stroke

- Clinically-significant infection within the last 30 days

- Myocardial infarction or symptoms of coronary artery disease (e.g., angina) in the
last two-years.

- Uncontrolled hypertension within the last 6 months

- History of cancer within the last 5 years (except non-metastatic basal or squamous
cell carcinoma)

- History of drug or alcohol abuse as defined by DSM-IV criteria within the last 2
years

- Presence of contraindications for MRI scanning (pacemaker, aneurysm clips, artificial
heart valves, metal fragments, foreign objects) or claustrophobia

- Insulin-dependent diabetes mellitus

- Significant pain or musculoskeletal disorder that would prohibit participation in an
exercise program
We found this trial at
1
site
3901 Rainbow Blvd
Kansas City, Kansas 66160
(913) 588-5000
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
?
mi
from
Kansas City, KS
Click here to add this to my saved trials